Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. - Wikidata - wikimedia - TriplyDB

Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.

Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.

http://www.wikidata.org/entity/Q38449826

about

Guanylate cyclase stimulators for pulmonary hypertension Guanylate cyclase stimulators for pulmonary hypertension Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management Left ventricular heart failure and pulmonary hypertension New insights into the role of soluble guanylate cyclase in blood pressure regulation Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction Potential new drug treatments for congestive heart failure.Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to left heart disease.Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Vasculopathy and pulmonary hypertension in sickle cell disease.Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trial.Riociguat: first global approval.Riociguat for pulmonary hypertension.Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure.Newest additions to heart failure treatment.Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction.New drugs and devices in the pipeline for heart failure with reduced ejection fraction versus heart failure with preserved ejection fraction.Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options.Pulmonary hypertension caused by pulmonary venous hypertension Controversies in pulmonary hypertension due to left heart disease Riociguat: Something new in pulmonary hypertension therapeutics?Role of sGC-dependent NO signalling and myocardial infarction risk.Riociguat: a novel new drug for treatment of pulmonary hypertension.Pulmonary Hypertension in Heart Failure. Epidemiology, Right Ventricular Function, and Survival.New medical therapies for heart failure.The pathophysiology of pulmonary hypertension in left heart disease.Riociguat for the treatment of pulmonary hypertension.Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction.Evolving Concepts of Pulmonary Hypertension Secondary to Left Heart Disease.Lung Circulation.Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?

P2860

Q24195067-D2321468-F5B8-440A-B051-7306D3C0E89D Q26470534-9D01B846-5841-4B32-88A8-CF2C0C5749F2 Q26750994-4AA6A190-0B3A-467F-988A-B3976599FAEE Q26778341-BB72FDA5-E4B1-4A0B-A3A9-75A46C0F5A65 Q27021422-69833674-D911-4CD2-8EBA-9436EC2AA7EE Q27021649-D89DE2D6-3458-4AD0-95BD-8CE865CFC847 Q27024279-0FBA1251-9CC6-4E5E-B876-76EEA0C88DD0 Q28073079-96B9C8A3-5391-4440-989D-BE13B5ADE255 Q30251531-57093C41-1009-446A-A746-270A3C38693F Q33565707-4D35957D-4E36-46ED-98D9-F8C38E1600EB Q33596457-A2C84372-13CC-4863-BA91-46AF269010DB Q33965866-C9439390-130A-4F1F-9736-A953AE1D61E0 Q34444990-5937FAA9-2556-497F-8549-A0130AEE2CEA Q34448355-83189972-7863-4BD6-AC4A-FCCCB8ADAF0E Q34782595-3AA222BD-7421-4123-93AB-FF7F0CA2C02B Q35075847-93FD2E74-792A-4DC8-BAE7-7B51DCF9443C Q35086394-2BF9130F-3C7C-4A4E-B4C5-D77C098E4110 Q37058596-A89FABF6-A3E3-4808-AC07-A4F79CAE8B6D Q37510689-A645DFDB-07A4-44D9-8940-BBD34E2B29CE Q38161841-962B854F-40BE-4B54-B090-34B4D497C21B Q38192059-AEE6B21B-C251-489F-8B11-6F2AEB9673A2 Q38202309-3765CF45-8EFE-4ACE-AEFE-090E4418DFEC Q38225739-6BADF5F5-AF00-4203-AFA3-62A062994184 Q38235602-E8DB7B51-074D-43C8-87A0-FF49431D2773 Q38248398-57B3D788-2BBE-458E-AB15-290EF062E4AF Q38263468-55DF4461-B7C7-4A32-A792-163A5E081BC0 Q38283873-1968A427-699D-4CFD-9462-5E9CE948C510 Q38327916-DAFAC067-6638-44FC-90F3-DF3059D00115 Q38364200-E0B67ED3-3CFA-4536-9741-055078A91471 Q38364678-3E6BFA59-3206-47B5-9AFE-A7EC32F49517 Q38367012-4D4F8ED5-DCBB-4899-82E2-A7FE06192959 Q38502798-54D5C9F0-3751-447C-9BAE-F3BF21E54BBB Q38548379-253F5A89-CEB2-47C6-99A7-BE313E1F0BEE Q38594785-08324F2B-500A-4F54-A974-9F3056420E85 Q38616615-C7D68E83-B9CD-4665-8ED4-B093931DD4D9 Q38645382-D32B9DD9-7E9E-4301-AC6B-F176B7D8904C Q38682382-5031AEAA-B64C-44AE-8481-BF9628244926 Q38737284-D4EA8A45-60D8-4E52-9BAD-9D065737E2F4 Q38804579-45B2D8EF-536B-441D-8B3D-C4D576E05FB7 Q38818606-9FEFBFDC-4B41-4517-868E-9EF16F53B132

P2860

Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.

http://www.wikidata.org/entity/Q38449826

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Riociguat for patients with pu ...... ose-ranging hemodynamic study.

@en

type

label

Riociguat for patients with pu ...... ose-ranging hemodynamic study.

@en

prefLabel

Riociguat for patients with pu ...... ose-ranging hemodynamic study.

@en

P1433

Q38449826-227C4AAA-C679-43E4-9A68-EA9D60070CE5

P1476

Q38449826-B9C0AB04-424A-44FD-B5D1-E6B23740BDA8

P2093

Q38449826-0417A484-76FE-4369-8A1C-B49A43C055AC

Q38449826-084709B3-F724-4695-A22F-2F5404EDF833

Q38449826-3A5E1E5C-8CF8-4249-840F-297D42114A4E

Q38449826-594360A5-C005-421C-8B2B-9776E5EBEF0E

Q38449826-6C063EA0-4777-427D-A994-47A0799825B4

Q38449826-85E9CA94-E9B5-4C27-9CEF-F5B2E37BE930

Q38449826-9C385434-EA9D-4DCF-A7F5-18D4483A0F07

Q38449826-CBF64D73-A330-40CC-B2C8-B7B5D5F95AAE

Q38449826-D2E983FC-9A6F-49AD-A1A5-D8F8D14F4AAF

Q38449826-D7B6387C-E162-4071-BFF7-989A4F9AEC57

P304

Q38449826-4E349C05-C238-411F-B53E-D7855CF8CEFB

P31

Q38449826-A7A189DD-B2FE-4A78-A3F3-65424D20CC43

P356

Q38449826-C0051B17-B237-4599-8227-B5ADEF49F766

P407

Q38449826-4FA1040A-5F11-4422-9E2C-796C8B58C1E2

P433

Q38449826-5E18D3FC-38EE-4C6E-8CDF-446304F8B9F9

P478

Q38449826-1B6FB3E8-BD3B-4CFE-82BF-22322A02BBA9

P50

Q38449826-220C411F-1174-4E73-9A4F-1E5C2F2965B0

Q38449826-C1CFE16E-99B4-4CFB-9190-4679D71C501B

P577

Q38449826-A97EC845-33A4-407E-A807-F743F861CC3F

P698

Q38449826-2369920A-F68F-49DE-9CE1-BA2F8E706727

P921

Q38449826-0BE8F4BE-3373-4755-9F2B-F14F8E232AE6

Q38449826-3EEB0523-6899-4776-8125-E1A8E49A99BA

Q38449826-474B042D-F56C-4C3C-8899-A2F8413F6C3B

Q38449826-52101858-3ABE-471A-81F4-52FA9F1724AA

P356

CIRCULATIONAHA.113.001458

P1433

P1476

Riociguat for patients with pu ...... dose-ranging hemodynamic study

@en

P2093

Andrea-Viviana Scalise

http://www.w3.org/2001/XMLSchema#string

Diana Bonderman

http://www.w3.org/2001/XMLSchema#string

Evangelos Michelakis

http://www.w3.org/2001/XMLSchema#string

Francis Boateng

http://www.w3.org/2001/XMLSchema#string

Left Ventricular Systolic Dysf ...... guat Trial (LEPHT) Study Group

http://www.w3.org/2001/XMLSchema#string

Lothar Roessig

http://www.w3.org/2001/XMLSchema#string

Marc J Semigran

http://www.w3.org/2001/XMLSchema#string

Ronald J Oudiz

http://www.w3.org/2001/XMLSchema#string

Stephan B Felix

http://www.w3.org/2001/XMLSchema#string

Veselin Mitrovic

http://www.w3.org/2001/XMLSchema#string

P304

502-511

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.113.001458

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

Ardeschir Ghofrani

P577

2013-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23775260

http://www.w3.org/2001/XMLSchema#string

P921